FDA Expert Committee Reviews Capricor Therapeutics' Duchenne Muscular Dystrophy Treatment
Adam Feuerstein and Andrew Joseph
Summary
The FDA's expert advisory committee is reviewing Capricor Therapeutics' experimental treatment for Duchenne muscular dystrophy (DMD), a severe genetic disorder that progressively weakens muscles. This regulatory review has been contentious, with significant debate surrounding the drug's efficacy and safety profile. The committee's recommendation will be crucial in determining whether the FDA approves this potential therapy for DMD patients, many of whom have limited treatment options. For Puerto Rico's families affected by this rare but devastating condition, FDA approval could expand access to innovative genetic therapies.
